Clinical Trial Update: CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluates cetuximab given for three weeks as neoadjuvant therapy for locally advanced tongue cancer/oral squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma
• Tongue Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Rabin Medical Center | Conditions: Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN